An unexpectedly sharp drop in China's exports sent the markets tumbling to a sharply lower open with the Dow plummeting 157 points to 17,987. Nasdaq plunged 52 points to 5,186.
On the upside
Ocular Therapeutix (Nasdaq: OCUL) entered a strategic collaboration, option and license agreement with Regeneron Pharmaceuticals to jointly develop a sustained release formulation of the vascular endothelial growth factor trap aflibercept to treat wet age-related macular degeneration.
ContraVir Pharmaceuticals (Nasdaq: CTRV) reported positive interim data from an ongoing Phase 2a multiple ascending dose clinical study of CMX157.
Ulta Salon, Cosmetics & Fragrance (Nasdaq: ULTA) lifted its third quarter earnings and revenue guidance.
On the downside
TG Therapeutics (Nasdaq: TGTX) amended the GENUINE Phase 3 clinical trial to eliminate the second part of the study.
Investors locked in profits on Freeport-McMoRan (NYSE: FCX).
Retreating crude oil prices weighed down shares of Chesapeake Energy (NYSE: CHK).
In the broad market, declining issues outpaced advancers by a margin of more than 5 to 1 on the NYSE and by more than 4 to 1 on Nasdaq. The broader S&P 500 plunged 20 points to 2,119. Bitcoin added $2 to $635.
